Overview

Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence

Status:
Terminated

Trial end date:
2012-01-01

Target enrollment:

Participant gender:

Summary

This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.

Phase:

Phase 1

Details

Lead Sponsor:

Brain & Spine Surgeons of New York

Treatments:

Bevacizumab